Xi'an ruixi Biological Technology Co

Home > Keywords >

Catalog	name	Description	price
R-R-2966	CID-1067700 CAS No.314042-01-8	CID-1067700 (ML282)/CAS No.314042-01-8 is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.	price>
R-C-1267	Kenpaullone CAS：142273-20-9	Kenpaullone is a potent inhibitor of CDK1/cyclin B(IC50=400 nM),CDK2/cyclin A (IC50=680 nM),CDK2/cyclin E(IC50=7.5uM)and CDK5/p25(IC50=850 nM).Kenpaullone inhibits CDK2/cyclin A,CDK2/cyclin E and CDK5/cyclin/p35(IC50 values are 0.68, 7.5 and 0.85 μM respectively).	price>
R-R-2967	Lonafarnib CAS No.193275-84-2	Lonafarnib (Sch66336)/CAS No.193275-84-2 is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.	price>
R-C-1268	GSK3787 CAS：188591-46-0	GSK-3787 is a selective and irreversible peroxisome proliferator-activated receptor delta(PPARdelta)antagonist with good pharmacokinetic properties. GSK3787 can antagonize PPARbeta/delta in vivo,thus providing a new strategy to delineate the functional role of a receptor with great potential as a therapeutic target for the treatment and prevention of disease.	price>
R-R-2968	Divarasib CAS No.2417987-45-0	Divarasib (GDC-6036)/CAS No.2417987-45-0 is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state.	price>
R-C-1269	L-779450 CAS： 303727-31-3	L-779450 is a potent,selective and ATP-competitive Raf kinase inhibitor(IC50=10 nM).L-779450 suppresses DNA synthesis and induces apoptosis in cells that proliferate in response to Raf-1 and A-Raf but not B-Raf.	price>
R-R-2969	BAY-293 CAS No.2244904-70-7	BAY-293/CAS No.2244904-70-7, a valuable chemical probe, blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS.	price>
R-C-1270	AZD2858 CAS：486424-20-8	AZD2858 is a potent and GSK-3 inhibitor with an IC50 of 68 nM.AZD-2858 inhibits tau phosphorylation at the S396 site,and it activates Wnt signaling pathway. AZD2858 has a substantial impact on fracture healing.The fractures healed with a bony callus without an obvious endochondral component,suggesting that AZD2858 drives mesenchymal cells into the osteoblastic pathway.	price>
R-R-2970	GGTI298 Trifluoroacetate CAS No.1217457-86-7	GGTI298 Trifluoroacetate/CAS No.1217457-86-7 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.	price>
R-C-1271	Rofecoxib CAS：162011-90-7	Rofecoxib is a nonsteroidal anti-inflammatory drug(NSAID)that has now been withdrawn over safety concerns.Rofecoxib exhibits anti-inflammatory,analgesic, and antipyretic activities in animal models.The mechanism of action of rofecoxib is believed to be due to inhibition of prostaglandin synthesis,via inhibition of cyclooxygenase-2(COX-2).At therapeutic concentrations in humans,rofecoxib does not inhibit the cyclooxygenase-1(COX-1)isoenzyme.Studies to elucidate the mechanism of action of fofecoxib in the acute treatment of migraine have not been conducted.	price>
R-R-2971	MBQ-167 CAS No.2097938-73-1	MBQ-167/CAS No.2097938-73-1 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.	price>
R-C-1272	NVP-231 CAS：362003-83-6	NVP-231 is a potent,specific,and reversible CerK inhibitor that competitively inhibits binding of ceramide to CerK. NVP-231 is active in the low nanomolar range on purified as well as cellular CerK and abrogates phosphorylation of ceramide,resulting in decreased endogenous C1P levels.When combined with another ceramide metabolizing inhibitor,such as tamoxifen,NVP-231 synergistically increased ceramide levels and reduced cell growth.Therefore.NVP-231 represents a novel and promising compound for controlling ceramide metabolism that may provide insight into CerK physiological function.	price>
R-R-2972	MRTX0902 CAS No.2654743-22-1	MRTX0902/CAS No.2654743-22-1 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10).	price>
R-C-1273	PCI-27483 CAS No. 871266-63-6	PCI-27483 is a reversible small-molecule inhibitor of activated factor VII (factor VIIa)with potential antineoplastic and antithrombotic activities.FVII,a serine protease,becomes activated(FVII)aupon binding with TF forming the FVIIa/TF complex,which induces intracellular signaling pathways by activating protease activated receptor 2(PAR-2).Upon subcutaneous administration,factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex,which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways,thereby inhibiting tumor cell proliferation,angiogenesis,and metastasis of TF-overexpressing tumor cells.	price>
R-R-2973	Opnurasib CAS No.2653994-08-0	Opnurasib (JDQ-443) (NVP-JDQ443)/CAS No.2653994-08-0 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.	price>
R-C-1274	BMS754807 CAS：1001350-96-4	BMS-754807 is an efficacious,orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.	price>
R-R-2974	LC-2 CAS No.2502156-03-6	LC-2/CAS No.2502156-03-6 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines.	price>
R-C-1275	JNJ 31020028 CAS No. 1094873-14-9	JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07,human;pIC50=8.22 rat);>100-fold selective versus human Y1/Y4/Y5 receptors.	price>
R-R-2975	RMC-6291 CAS No.2641998-63-0	RMC-6291/CAS No.2641998-63-0 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. RMC-6291 also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM.	price>
R-C-1276	CHS 828 CAS：200484-11-3	CHS-828(GMX1778)is a competitive inhibitor of nicotinamide phosphoribosyltransferase(NAMPT),with an IC50 less than 25 nM.CHS-828 (GMX1778)exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity.	price>

507508509510511512 513514515516517